Novo Nordisk has planted another seed to fuel the blossoming of its obesity business, inking an $812 million deal with Deep ...

In the shadow of President Trump's efforts to lower drug prices, the Medicare drug price negotiation process that began in ...

The U.S.-listed shares of Danish drugmaker Novo Nordisk rose Tuesday following a report that an activist investor is building ...

PITTSBURGH (CN) — Bashing a Biden-era law that gives Medicare the power to directly negotiate the price of certain high-cost prescription drugs, an attorney for the pharmaceutical giant Novo Nordisk ...

Novo Nordisk will pay U.S. biotech Deep Apple Therapeutics up to $812 million in a partnership deal aimed at developing drugs to treat cardiometabolic diseases, including obesity.

Novo Nordisk NVO shares have gained 13.9% in the ... CagriSema demonstrated a lower-than-expected reduction in body weight. Last month, Medicare announced that it will not cover costly weight ...

Novo Nordisk has launched a new late-stage trial for its experimental next-generation obesity drug candidate, CagriSema, as ...

Despite the price drops, the drugs remain costly. Novo Nordisk cut the price of Wegovy by 23 percent for cash payments from $650 to $499 for uninsured patients or people without coverage. The drug’s ...

The percentage of adults prescribed a GLP-1 drug like Wegovy or Zepbound jumped almost sevenfold over the past five years, ...

Novo Nordisk had a head start ... and some have refused to cover them. In most cases, Medicare will not pay for the drugs to treat obesity. The Trump administration recently rejected a Biden ...